A Synthetic Peptide AWRK6 Combined with Epigallocatechin Gallate Alleviates Type 2 Diabetes in Mice

The treatment of diabetes is facing severe challenges globally. Recent advances of peptide AWRK6 and epigallocatechin gallate (EGCG) indicated novel potential strategies against type 2 diabetes. Here, the combined administration of AWRK6 and EGCG was investigated in mice with type 2 diabetes. Compared with control group, the blood glucose was significant reduced and the body weight was inhibited. The dyslipidemia and damage of antioxidant capacity were found to be restored using biochemical analysis methods. For mechanisms, western blotting was applied and it was found that PI3K/AKT signaling pathway was involved in the therapeutic effects of AWRK6 and EGCG. In summary, AWRK6 combined with EGCG could alleviate type 2 diabetes in mice. It presented a novel potential strategy against type 2 diabetes.